Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML
Open Access
Abstract
In recent years, treatments in the field of hematologic malignancies have undergone significant evolution; allogeneic hematopoietic stem cell transplantation (allo-HSCT) has shifted from an “ultimate” therapy to becoming a component of a comprehensive therapeutic strategy for acute myeloid leukemia (AML). Advances in risk stratification (including molecular profiling and measurable residual disease assessment), conditioning regimens, and graft-versus-host disease (GVHD) prophylaxis—such as post-transplant cyclophosphamide—have improved outcomes and expanded donor selection and transplant eligibility. We should not only focus on the transplantation procedure but also consider various therapeutic components, including chemotherapy, targeted therapy (possibly including chimeric antigen receptor T-cell therapy), and post-transplant maintenance therapy, which need to be orchestrated within the broader context of leukemia treatment. In this review, we summarized key developments in allo-HSCT for AML and aim to “decipher” each component of transplantation.Keywords
Funding Information
- Arlene Witmer Memorial Fund for Bone Marrow Cancer Research
- John and Denise Gilliland Fund for the Cancer Genetics Program
- G. R. Sponaugle Employee Cancer Research Fund
- Earl “Bumps” Clouser Memorial Lymphoma Research Endowment, Megan and Andrew Enders Stewardship
- Richard E. and Stephanie A. Ziegler Charitable Foundation Endowment in Hematology
This publication has 147 references indexed in Scilit:
- Update in GVHD Prophylaxis: Novel Pharmacologic and Graft Manipulation StrategiesAmerican Journal of Hematology, 2025
- Prediction and Prognostication of Acute Graft‐Versus‐Host Disease by MAGIC BiomarkersAmerican Journal of Hematology, 2025
- Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid LeukemiaJAMA Oncology, 2023
- Additional cytogenetic features determine outcome in patients allografted for TP53 mutant acute myeloid leukemiaCancer, 2022
- Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survivalAmerican Journal of Hematology, 2022
- Phase II clinical trial of one dose of post‐transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched‐unrelated donor transplantationAmerican Journal of Hematology, 2021
- Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplantAmerican Journal of Hematology, 2017
- History of consolidation is prognostic in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in minimal residual disease‐negative first complete remissionAmerican Journal of Hematology, 2017
- Impact of postremission consolidation chemotherapy on outcome after reduced‐intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: A report from the Acute Leukemia Working Party of the European Group for Blood and Marrow TransplantationCancer, 2013
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009